Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2015 Publisher: Mercury Pharmaceuticals Ltd, Capital House, 85 King William Street, London EC4N 7BL, UK
Do not use in patients who have had a cerebrovascular accident; or in the recovery period (usually 3-4 weeks) after acute myocardial infarction.
Use with great caution in patients in whom a fall in blood pressure and/or tachycardia may be undesirable, such as the elderly or those with severe heart disease, congestive heart failure, cerebrovascular disease or renal damage. The mode of action should be borne in mind, if used concurrently with α-sympatho-mimetics or myocardial depressants.
Phenoxybenzamine is carcinogenic in the rat and has shown mutagenic activity in the bacterial Ames test and mouse lymphoma assay. It should only be used after very careful consideration of the risks, in patients in which alternative treatment is inappropriate.
See under Special Precautions and Warnings.
There is little evidence of safety of Dibenyline in pregnancy and it should not be used in pregnancy unless essential.
None known.
Side effects are generally mild and transient, but may include postural hypotension with dizziness and compensatory tachycardia, nasal congestion, inhibition of ejaculation, miosis and lassitude. Gastro-intestinal upset has also been reported.
None known.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
